What Are the Early Symptoms of PML in Tysabri Patients?
Latest update (2026-07)
Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Literacy to Specific Exposure Risks
If you or a loved one is taking Tysabri, understanding the early signs of progressive multifocal leukoencephalopathy (PML) can be life-saving. Symptoms such as progressive weakness, vision changes, or confusion may appear subtly. The medical community has long recognized the importance of monitoring for these neurological changes to enable timely intervention. This page outlines the specific symptoms to track and why prompt medical attention matters.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in New York who have developed PML after Tysabri treatment, understanding the medical evidence and legal timelines is critical. PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, visual changes, cognitive decline, and coordination problems. Diagnosis typically involves MRI imaging and detection of JC virus DNA in cerebrospinal fluid. Because PML can progress rapidly, the label instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Mechanistic Pathways and Adequacy of Warnings
The mechanistic link between Tysabri and PML involves the drug's mechanism of action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs normal immune surveillance. In patients who harbor JC virus, this reduced immune surveillance can allow the virus to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The prescribing information for Tysabri contains a boxed warning that clearly states the increased risk of PML and identifies the three major risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also notes that Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read a Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether the warnings were adequate in specific cases, particularly regarding the communication of risk to individual patients and the timing of risk assessments.
Settlement-Related Considerations and Statute of Limitations in New York
For patients in New York who have developed PML after Tysabri treatment, settlement considerations may involve the timeline between exposure and documented harm. PML can occur after varying durations of Tysabri therapy, with risk increasing after two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The onset of symptoms may be gradual, and diagnosis can be delayed. The statute of limitations for product liability claims in New York generally requires that a lawsuit be filed within three years of the date of injury or, in some cases, within three years of when the injury was discovered or should have been discovered. For PML, the date of injury may be the date of diagnosis or the date when symptoms first appeared, depending on the specific circumstances. Patients and their families should be aware that the statute of limitations can vary based on the type of claim (e.g., negligence, failure to warn, or strict liability) and the specific facts of the case. It is important to consult with a legal professional experienced in pharmaceutical litigation to determine the applicable deadlines.
Conclusion and Next Steps
Tysabri therapy carries a known risk of PML, with identified risk factors including anti-JCV antibody status, treatment duration, and prior immunosuppressant use. The prescribing information includes boxed warnings and a restricted distribution program to mitigate this risk. For New York patients who have developed PML, the statute of limitations for legal action is typically three years from the date of injury or discovery. Given the severity of PML and the complexity of the legal timelines, prompt consultation with both medical and legal professionals is advisable.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri-related PML claims in New York?
In New York, the statute of limitations for product liability claims, including those related to Tysabri and PML, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For PML, the date of injury may be the date of diagnosis or the date symptoms first appeared. It is important to consult with a legal professional to determine the exact deadline for your case.
What are the risk factors for developing PML while on Tysabri?
Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.